NCT02351011View on ClinicalTrials.gov

Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Osteoarthritis of Knee
Interventions
BIOLOGICAL

1 x 10^6 MSCs

Autologous, bone-marrow derived MSCs

BIOLOGICAL

10 x 10^6 MSCs

Autologous, bone-marrow derived MSCs

BIOLOGICAL

50 x 10^6 MSCs

Autologous, bone-marrow derived MSCs

Trial Locations (1)

M5T 2S8

Toronto Western Hospital, Toronto

All Listed Sponsors
lead

Jas Chahal

OTHER

NCT02351011 - Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA | Biotech Hunter | Biotech Hunter